

20 December 2024



Melissa Kostopoulos
Listing Compliance - Melbourne
ASX Compliance Pty Ltd
525 Collins Street
North Tower Level 4
MELBOURNE VIC 3000

By email: melissa.kostopoulos@asx.com.au

Dear Melissa

Pursuant to ASX Listing Rule 17.1, Rhythm Biosciences Limited ACN 619 459 335 (**Company**) requests an immediate trading halt be granted by ASX in respect to the Company's ordinary shares.

For the purposes of ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- a) The trading halt is requested pending an announcement in relation to a proposed acquisition;
- b) The Company requests that the trading halt end on the earlier of the commencement of normal trading on 24 December 2024, or when the anticipated announcement referred to in (a) above is released to the market; and
- c) The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Released with the authority of the Board.

Yours sincerely

A handwritten signature in blue ink, appearing to read "A. Steele".

Andrea Steele
Joint Company Secretary

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors

Otto Buttula
Sue MacLeman
Gavin Fox-Smith
David Atkins

Non-Executive Chairman
Non-Executive Director
Non-Executive Director
CEO & Managing Director